Sep 29, 2025 8:30am EDT Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference
Sep 10, 2025 8:30am EDT Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
Sep 03, 2025 11:33am EDT Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results
Sep 03, 2025 8:45am EDT Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
Aug 25, 2025 7:55am EDT Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Aug 13, 2025 8:00am EDT Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
Aug 11, 2025 9:15am EDT Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13
